Literature DB >> 8131780

Infection and inflammation as risk factors for myocardial infarction.

M S Nieminen1, K Mattila, V Valtonen.   

Abstract

Recent studies have illustrated that in addition to the well known risk factors, such as lipoproteins, smoking, hypertension, there are others that cause atherosclerosis and myocardial infarction. Our knowledge of atherosclerotic lesions has increased. We now know that atherosclerotic changes are due to inflammatory cell infiltration as well as to increases in migration of vascular smooth muscle cells. Endothelial cells play a major role in the pathology of vascular changes. In recent years a new risk factor for coronary artery disease has been discovered: chlamydia pneumonial infections. Herpes class viruses have also been associated with pathology of atherosclerotic lesions. Studies show that dental status and bacterial infections are also related to the risk of myocardial infarction. This review discusses the possible mechanisms of infection and inflammation and whether they are major or modifying risk factors for atherosclerosis and myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8131780

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  18 in total

1.  Circulating immune complexes and complement C4 null alleles in patients in patients operated on for premature atherosclerotic peripheral vascular disease.

Authors:  S Nityanand; L Truedsson; A Mustafa; C Bergmark; A K Lefvert
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

2.  Fusobacterium nucleatum transports noninvasive Streptococcus cristatus into human epithelial cells.

Authors:  Andrew M Edwards; Tracy J Grossman; Joel D Rudney
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  The contribution of tumour necrosis factor-alpha and endothelin-1 to the increase of coronary resistance in hearts from rats treated with endotoxin.

Authors:  T Hohlfeld; P Klemm; C Thiemermann; T D Warner; K Schrör; J R Vane
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 4.  The conundrum of time trends in stroke.

Authors:  C R Gale; C N Martyn
Journal:  J R Soc Med       Date:  1997-03       Impact factor: 5.344

5.  Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR.

Authors:  B Farsak; A Yildirir; Y Akyön; A Pinar; M Oç; E Böke; S Kes; L Tokgözoğlu
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

6.  Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms.

Authors:  F Blasi; F Denti; M Erba; R Cosentini; R Raccanelli; A Rinaldi; L Fagetti; G Esposito; U Ruberti; L Allegra
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

7.  Bacterial lipopolysaccharide and tumor necrosis factor alpha synergistically increase expression of human endothelial adhesion molecules through activation of NF-kappaB and p38 mitogen-activated protein kinase signaling pathways.

Authors:  H P Jersmann; C S Hii; J V Ferrante; A Ferrante
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

8.  Helicobacter pylori eradication ameliorates primary Raynaud's phenomenon.

Authors:  A Gasbarrini; I Massari; M Serricchio; P Tondi; A De Luca; F Franceschi; V Ojetti; A Dal Lago; R Flore; A Santoliquido; G Gasbarrini; P Pola
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

9.  Association of markers of systemic inflammation, C reactive protein, serum amyloid A, and fibrinogen, with socioeconomic status.

Authors:  P Jousilahti; V Salomaa; V Rasi; E Vahtera; T Palosuo
Journal:  J Epidemiol Community Health       Date:  2003-09       Impact factor: 3.710

10.  Periodontitis as a risk factor for cardiovascular disease: the role of anti-phosphorylcholine and anti-cardiolipin antibodies.

Authors:  K Karnoutsos; P Papastergiou; S Stefanidis; A Vakaloudi
Journal:  Hippokratia       Date:  2008-07       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.